NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

It is a new patent with controllable chain length of poly-iclc. Here is the part taken from the patent.

The size of the poly-I and poly-C components of poly-ICLC (or previously, poly-IC) has been correlated to efficiency of interferon induction (Levy 1981 ). More recently the mechanism of this differential effect has been further elucidated. For example, short poly-IC preferentially activates the RIG-1 helicase with certain antiviral effects, while long chain poly-IC activates the MDAS helicase, resulting in a broader immunomodulation, adjuvant and anti inflammatory action. Nevertheless because of the complex and inter-related clinical actions of Poly-ICLC, the overall correlation between polyribonucleotide component size and each facet of biological activity is not fully understood. Despite Jacking complete understanding, it is clear that precise control of the size of the polyribonucleotide components is a highly desirable element of any production method. Targeting specific molecular weight ranges may enhance activity toward a certain indication or reduce toxicity at effective dose levels. To date, however, a reliable method of producing Poly-ICLC with a desired range of molecular weights has been unavailable.